Krystal Biotech (NASDAQ:KRYS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Separately, Ladenburg Thalmann Financial Services began coverage on shares of Krystal Biotech in a report on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price target for the company.

Krystal Biotech (NASDAQ:KRYS) opened at $8.85 on Tuesday. Krystal Biotech has a fifty-two week low of $8.03 and a fifty-two week high of $11.98.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 13th. The company reported ($1.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.52). equities research analysts anticipate that Krystal Biotech will post -1.85 earnings per share for the current year.

In other Krystal Biotech news, COO Suma Krishnan purchased 100,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was acquired at an average cost of $10.00 per share, with a total value of $1,000,000.00. Following the acquisition, the chief operating officer now owns 1,935,249 shares of the company’s stock, valued at approximately $19,352,490. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel Janney purchased 200,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was acquired at an average cost of $10.00 per share, with a total value of $2,000,000.00. The disclosure for this purchase can be found here.

An institutional investor recently bought a new position in Krystal Biotech stock. Highbridge Capital Management LLC acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 300,000 shares of the company’s stock, valued at approximately $2,991,000. Highbridge Capital Management LLC owned about 3.11% of Krystal Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 30.72% of the company’s stock.

WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/krystal-biotech-krys-stock-rating-lowered-by-zacks-investment-research/1776116.html.

Krystal Biotech Company Profile

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.